Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Alterity Therapeutics Limited
ATHE | US
4.41
USD0.04
0.92%
ATHE | US
Loading StockChartView...
About Alterity Therapeutics Limited
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
4.41
Open
4.30
High
4.70
Low
4.30
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease Huntington disease Parkinson's disease and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne Australia.
View LessATHE | US
Risk
97.6
Sharpe
0.27
Luna's Score
55/100
Recommendation
Hold
Luna says (ATHE | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
114.6%1 month
97.6%3 months
71.1%6 months
67.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.14
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.75
Ent. to rev.
113.99
PEG
-
Other Fundamentals
EBITDA
-19.57M
MarketCap
38.56M
MarketCap(USD)
38.56M
Div. yield
-
Op. margin
-612.91
Erngs. growth
-
Rev. growth
38.40
Ret. on equity
-104.47
Short ratio
0.87
Short perc.
0.11
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.75
Range1M
2.16
Range3M
2.23
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.39
Price X volume
36.29K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.75 | 0.53 | Expensive |
| Ent. to Revenue | 113.99 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.14 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 71.11 | 72.80 | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 38.56M | 3.66B | Emerging |
